Consider that when Pluvicto (Lutetium-177) went through clinical trials, it was only intended for those who had already exhausted all other treatment options; this was their treatment of last resort. Since then, there have been clinical trials demonstrating its efficacy earlier in treatment of the disease - but, not as the first line of treatment.

So, it’s not about being “50 and want to give Pluvicto a try” or about fighting with insurance companies.

It’s about whether or not you meet the eligibility criteria for use, which is generally for those who have failed standard of care treatments, and have:
> PSMA-positive metastatic castration-resistant prostate cancer, who have already received 1-2 chemotherapy regimens and androgen receptor pathway inhibitors (ARPIs).

If you meet those criteria, and your treatments aren’t working, then you may be a candidate.

(During April-May 2021, I had 28 sessions of proton radiation + 6 months of ADT for a localized 7(4+3); Medicare paid for it all.)